Page 50 - congress

ORAL PRESENTATION / TAM METİN SÖZLÜ SUNUM

Imabayashi K, Ayano M, Higashioka K, Yokoyama K, Yamamoto K, Takayama K, et al. (2021).
Infliximab for reversible dementia in acute onset of neuro-Behçet's disease: A case report
and cytokine analysis. J Neuroimmunol. 357:577631.
Jasenovec T, Radosinska D, Jansakova K, Kopcikova M, Tomova A, Snurikova Det al. (2023).
Alterations in antioxidant status and erythrocyte properties in children with autism
spectrum disorder. Antioxidants. 12(12):2054.
Jou RJ, Minshew NJ, Keshavan MS, Vitale MP, Hardan AY. (2010). Enlarged right superior temporal
gyrus in children and adolescents with autism. Brain Res. 1360:205-212.
Kalinowska-Lyszczarz A, Fereidan-Esfahani M, Guo Y, Lucchinetti CF, Tobin WO. (2020).
Pathological findings in central nervous system demyelination associated with infliximab.
Mult Scler J. 26(9):1124-1129.
Khaliulin I, Hamoudi W, Amal H. (2025). The multifaceted role of mitochondria in autism spectrum
disorder. Mol Psychiatry. 30(2):629-650.
Kikuchi H, Aramaki K, Hirohata S. (2008). Effect of infliximab in progressive neuro-Behçet's
syndrome. J Neurol Sci. 272(1-2):99-105.
Manivasagam T, Arunadevi S, Essa MM, SaravanaBabu C, Borah A, Thenmozhi AJ, Qoronfleh MW.
(2020). Role of oxidative stress and antioxidants in autism. In: Personalized Food
Intervention and Therapy for Autism Spectrum Disorder Management. 193-206.
Meguid NA, Dardir AA, Abdel-Raouf ER, Hashish A. (2011). Evaluation of oxidative stress in autism:
defective antioxidant enzymes and increased lipid peroxidation. Biological Trace Element
Research. 143(1):58-65.
Mehan S, Kumar A, Sharma T, Khan Z, Tiwari A, Gupta GD, Narula AS. (2025). Therapeutic efficacy
of Genistein in activation of neuronal AC/cAMP/CREB/PKA and mitochondrial ETC-Complex
pathways in experimental model of autism: Evidence from CSF, blood plasma and brain
analysis. Brain Research. 1846:149251.
Nasrallah O, Alzeer S. (2022). Measuring some oxidative stress biomarkers in autistic Syrian
children and their siblings: a case-control study. Biomarker Insights.
17:11772719221123913.
Ornoy A, Weinstein-Fudim L, Tfilin M, Ergaz Z, Yanai J, Szyf M, Turgeman G. (2019). S-adenosyl
methionine prevents ASD like behaviors triggered by early postnatal valproic acid exposure
in very young mice. Neurotoxicology and Teratology. 71:64-74.
Poutoglidou F, Pourzitaki C, Manthou ME, Saitis A, Malliou F, Kouvelas D. (2021). Infliximab and
tocilizumab reduce anxiety-like behavior, improve cognitive performance and reverse
neuropathological alterations in juvenile rats with severe autoimmune arthritis.
International Immunopharmacology. 99:107917.
Psarelis S, Hajineocli AP, Hadjicosta E, Elliott HSA, Johnson P. (2017). Is secukinumab a safe
alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-
α treatment? Case report and literature review. Clinical Rheumatology. 36(5):1197-1199.
Rahmati-Dehkordi F, Birang N, Jalalian MN, Tamtaji Z, Dadgostar E, Aschner M, et al. (2025). Can
infliximab serve as a new therapy for neuropsychiatric symptoms? Naunyn-Schmiedeberg's
Archives of Pharmacology. 398(2):1081-1097.
Rajabi P, Noori AS, Sargolzaei J. (2024). Autism spectrum disorder and various mechanisms
behind it. Pharmacology Biochemistry and Behavior. 245:173887.
Şahin TD, Gocmez SS, Duruksu G, Yazir Y, Utkan T. (2020). Infliximab prevents dysfunction of the
vas deferens by suppressing inflammation and oxidative stress in rats with chronic stress.
Life Sciences. 250:117545.
Tadas M, Wankhede N, Chandurkar P, Kotagale N, Umekar M, Katariya R, et al. (2025). Postnatal
propionic acid exposure disrupts hippocampal agmatine homeostasis leading to social

48